| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Maastricht Radiation Oncology Maastricht University Medical Center |
| Information provided by: | Maastricht Radiation Oncology |
| ClinicalTrials.gov Identifier: | NCT00157365 |
Purpose
The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.
| Condition |
|
Bladder Cancer |
| Genetics Home Reference related topics: | bladder cancer |
| MedlinePlus related topics: | Bladder Cancer Cancer |
| Study Type: | Observational |
| Study Design: | Screening, Longitudinal, Defined Population, Prospective Study |
| Official Title: | Storing Blood for Analysis of DNA and Protein of Patients With Bladder Cancer in MAASTRO Clinic |
| Estimated Enrollment: | 99 |
| Study Start Date: | June 2003 |
| Estimated Study Completion Date: | June 2025 |
It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to draw blood in MAASTRO clinic of all patients with bladder cancer and store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Philippe Lambin, Prof PHD | +31 (0) 88 44 55 666 | philippe.lambin@maastro.nl |
| Contact: Dirk De Ruysscher, PHD | +31 (0) 88 44 55 666 | dirk.deruysscher@maastro.nl |
| Netherlands, Limburg | |||||
| Maastricht Radiation Oncology | Recruiting | ||||
| HEERLEN, Limburg, Netherlands, 6419 PC | |||||
| Contact: Dirk De Ruysscher, PHD +31 (0) 88 44 55 666 dirk.deruysscher@maastro.nl | |||||
| Contact: Francis Van Gils, PHD +31 (0) 88 44 55 666 francis.vangils@maastro.nl | |||||
| Maastricht Radiation Oncology |
| Maastricht University Medical Center |
| Principal Investigator: | Dirk De Ruysscher, PHD | CCMO |
More Information
| Study ID Numbers: | P03.0607L |
| First Received: | September 8, 2005 |
| Last Updated: | April 24, 2007 |
| ClinicalTrials.gov Identifier: | NCT00157365 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
|
|
|
|
